Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | Feb 01 | Option Exercise | 0.00 | 2,543 | 0 | 2,543 | Feb 03 07:18 PM | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Dec 02 | Option Exercise | 0.00 | 2,637 | 0 | 44,603 | Dec 06 07:32 PM | Elkins David V | EVP, Chief Financial Officer | Dec 02 | Option Exercise | 0.00 | 8,792 | 0 | 128,578 | Dec 06 06:44 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Dec 02 | Option Exercise | 0.00 | 8,792 | 0 | 65,871 | Dec 06 06:43 PM | Powell Ann | EVP, Chief Human Resources | Nov 09 | Sale | 80.45 | 16,250 | 1,307,312 | 34,226 | Nov 14 06:57 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Nov 07 | Option Exercise | 58.31 | 52,604 | 3,067,529 | 102,989 | Nov 09 08:38 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Nov 07 | Sale | 78.88 | 45,910 | 3,621,381 | 57,079 | Nov 09 08:38 PM | Caforio Giovanni | Board Chair and CEO | Sep 20 | Sale | 69.71 | 25,000 | 1,742,750 | 476,104 | Sep 22 05:12 PM | Caforio Giovanni | Board Chair and CEO | Sep 15 | Sale | 71.84 | 50,000 | 3,592,000 | 501,104 | Sep 16 05:12 PM | Powell Ann | EVP, Chief Human Resources | Sep 14 | Sale | 70.75 | 25,000 | 1,768,750 | 50,476 | Sep 15 07:29 PM | Elkins David V | EVP, Chief Financial Officer | Sep 13 | Option Exercise | 48.49 | 123,277 | 5,977,702 | 223,737 | Sep 15 07:29 PM | Elkins David V | EVP, Chief Financial Officer | Sep 13 | Sale | 71.30 | 133,951 | 9,551,167 | 100,460 | Sep 15 07:29 PM | Weese Michelle | EVP, Corporate Affairs | Jul 01 | Option Exercise | 0.00 | 1,885 | 0 | 1,885 | Jul 05 04:29 PM | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Jul 01 | Option Exercise | 0.00 | 9,356 | 0 | 26,078 | Jul 05 04:28 PM | Caforio Giovanni | Board Chair and CEO | Jun 13 | Sale | 74.04 | 30,000 | 2,221,200 | 551,104 | Jun 14 05:58 PM | LEUNG SANDRA | EVP, General Counsel | Jun 06 | Sale | 74.89 | 65,000 | 4,867,850 | 308,627 | Jun 07 05:49 PM | Haller Julia A | Director | Jun 03 | Option Exercise | 0.00 | 2,949 | 0 | 13,619 | Jun 07 05:50 PM | Mily Elizabeth | EVP, Strategy & BD | Apr 01 | Option Exercise | 0.00 | 6,347 | 0 | 12,481 | Apr 04 06:13 PM | Caforio Giovanni | Board Chair and CEO | Mar 21 | Sale | 71.52 | 25,000 | 1,788,000 | 581,524 | Mar 23 07:43 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Mar 16 | Option Exercise | 57.00 | 47,305 | 2,696,612 | 93,613 | Mar 18 05:50 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Mar 16 | Sale | 69.25 | 74,559 | 5,162,973 | 46,308 | Mar 18 05:50 PM | Santiago Karen Murphy | SVP & Controller | Mar 14 | Sale | 69.19 | 6,577 | 455,096 | 16,704 | Mar 16 07:32 PM | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Mar 14 | Sale | 69.20 | 29,532 | 2,043,526 | 41,966 | Mar 16 07:32 PM | Caforio Giovanni | Board Chair and CEO | Mar 10 | Option Exercise | 0.00 | 239,501 | 0 | 653,392 | Mar 14 09:20 PM | LEUNG SANDRA | EVP, General Counsel | Mar 10 | Option Exercise | 0.00 | 60,273 | 0 | 388,747 | Mar 14 09:20 PM | Elkins David V | EVP, Chief Financial Officer | Mar 10 | Option Exercise | 0.00 | 16,067 | 0 | 134,133 | Mar 14 09:18 PM | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Mar 10 | Option Exercise | 0.00 | 51,715 | 0 | 81,649 | Mar 14 09:19 PM | Powell Ann | EVP, Chief Human Resources | Mar 10 | Option Exercise | 0.00 | 35,686 | 0 | 78,829 | Mar 14 09:17 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Mar 10 | Option Exercise | 0.00 | 15,247 | 0 | 81,213 | Mar 14 09:16 PM | Santiago Karen Murphy | SVP & Controller | Mar 10 | Option Exercise | 0.00 | 11,073 | 0 | 24,489 | Mar 14 09:16 PM | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | Mar 10 | Option Exercise | 0.00 | 9,074 | 0 | 18,953 | Mar 14 09:17 PM | Mily Elizabeth | EVP, Strategy & BD | Mar 10 | Option Exercise | 0.00 | 4,005 | 0 | 8,246 | Mar 14 09:16 PM | Elkins David V | EVP, Chief Financial Officer | Mar 01 | Option Exercise | 0.00 | 24,577 | 0 | 132,034 | Mar 03 05:33 PM | VESSEY RUPERT | EVP, Research & Early Dev. | Mar 01 | Option Exercise | 0.00 | 23,350 | 0 | 79,587 | Mar 03 05:33 PM | Caforio Giovanni | Board Chair and CEO | Feb 24 | Sale | 67.00 | 30,000 | 2,010,000 | 453,455 | Feb 28 04:44 PM |
|